SOMERSET, N.J. / Jun 02, 2023 / Business Wire / Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will participate in the upcoming investor conferences:
Event: Jefferies Healthcare Conference
Location: New York, NY
Fireside Chat Date & Time: Wednesday, June 7, 2023 at 1:30pm ET
Presenter: Ying Huang, Ph.D., CEO
Event: Goldman Sachs 44th Annual Global Healthcare Conference
Location: Dana Point, CA
Fireside Chat Date & Time: Wednesday, June 14, 2023 at 8:00am PT
Presenter: Ying Huang, Ph.D., CEO
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.
| Last Trade: | US$26.69 |
| Daily Change: | -0.15 -0.56 |
| Daily Volume: | 1,724,982 |
| Market Cap: | US$4.930B |
November 13, 2025 November 12, 2025 November 03, 2025 June 03, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
